http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 06:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jul+08/26764444.html si-local-file:///var/storage/secattach/20260714/26764444.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jul+08/26764444.html Tue, 14 Jul 2026 06:30:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jul+08/26764444.html si-local-file:///var/storage/secattach/20260714/26764444.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jul+08/26764444.html Tue, 14 Jul 2026 06:30:00 -0400 O.30518154 SPRO http://www.streetinsider.com/Investing/Spero+Therapeutics+shares+fall+after+%24105M+KKR+deal/26764363.html <p>Investing.com -- Spero Therapeutics Inc. shares traded about 12% lower in pre-market hours Tuesday following the company's announcement of a $105 million licensing agreement with affiliates of Healthcare Royalty, a business of KKR.</p><p>The clinical-stage biopharmaceutical company said HCRx will receive a portion of future milestone and royalty payments from sales of Utebzi, also known as tebipenem pivoxil. Spero plans to use the funds primarily to support development of SP001, its lead immunology drug candidate currently in Phase 2.</p><p>"Over the past year, in collaboration with GSK, we successfully advanced Utebzi through FDA approval, while executing on our strategy to strengthen Spero http://www.streetinsider.com/Investing/Spero+Therapeutics+shares+fall+after+%24105M+KKR+deal/26764363.html Tue, 14 Jul 2026 06:21:08 -0400 KKR SPRO http://www.streetinsider.com/Investing/Spero+Therapeutics+shares+fall+after+%24105M+KKR+deal/26764363.html <p>Investing.com -- Spero Therapeutics Inc. shares traded about 12% lower in pre-market hours Tuesday following the company's announcement of a $105 million licensing agreement with affiliates of Healthcare Royalty, a business of KKR.</p><p>The clinical-stage biopharmaceutical company said HCRx will receive a portion of future milestone and royalty payments from sales of Utebzi, also known as tebipenem pivoxil. Spero plans to use the funds primarily to support development of SP001, its lead immunology drug candidate currently in Phase 2.</p><p>"Over the past year, in collaboration with GSK, we successfully advanced Utebzi through FDA approval, while executing on our strategy to strengthen Spero http://www.streetinsider.com/Investing/Spero+Therapeutics+shares+fall+after+%24105M+KKR+deal/26764363.html Tue, 14 Jul 2026 06:21:08 -0400 KKR SPRO http://www.streetinsider.com/Equity+Offerings/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Equity+Offerings/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Equity+Offerings/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Equity+Offerings/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Corporate+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Corporate+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Corporate+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Corporate+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Hot+Corp.+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Hot+Corp.+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Hot+Corp.+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html <p>Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of HealthCare Royalty (HCRx), a business majority owned by KKR & Co. Inc. (NYSE: KKR).</p><p>Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi (tebipenem pivoxil), an antibiotic recently approved by the U.S. Food and Drug Administration for complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in most territories, with Meiji holding rights in certain parts of Asia.</p><p>HCRx will provide Spero with a $105 million payment at http://www.streetinsider.com/Hot+Corp.+News/Spero+Therapeutics+secures+%24105M+royalty-backed+financing+deal/26764280.html Tue, 14 Jul 2026 06:04:37 -0400 KKR SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html <ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside </em></li><li><em>Spero updates its cash runway guidance into the second half of 2029</em><br/></li></ul> <p>CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9tg1uoaIJ7r-v1eXz1ZgfUwTf5KScwothNpm2coXIAIlUdieutbi82NnEoBWPZDfRdop-8U6F6ruVNK4vMod6NQM6GT-Xqpc4VbBKQI_v2g=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+%24105+Million+Non-Recourse+Non-Dilutive+Financing+Backed+by+a+Portion+of+Utebzi+Milestones+%26amp%3B+Royalties/26764149.html Tue, 14 Jul 2026 06:02:00 -0400 A.05850503 A.13486983 A.50202447 KKR O.03616677 O.10144505 O.14891823 O.30518154 O.51351764 SPRO